Paramomycin

# Paramomycin ## Overview - **Classification**: Aminoglycoside antibiotic - **Mechanism**: Inhibits protein synthesis by binding to the 16S ribosomal RNA, leading to misreading of the mRNA and premature termination. Acts locally in the GI tract due to poor systemic absorption. ## Primary Indications 1. **Intestinal Amebiasis** - Treatment of asymptomatic or symptomatic intestinal infection caused by *Entamoeba histolytica*. 2. **Cryptosporidiosis** - (Off-label) Treatment of diarrhea caused by *Cryptosporidium parvum*, primarily in immunocompromised patients (e.g., HIV/AIDS). ## Adult Dosing ### Standard Dosing **Intestinal Amebiasis** - **Dose**: **25-35 mg/kg/day** - **Frequency**: Divided into 3 doses (TID) - **Route**: Oral - **Duration**: **5-10 days** (usually 7 days) **Cryptosporidiosis** - **Dose**: **25-35 mg/kg/day** (some sources up to **50 mg/kg/day**) - **Frequency**: Divided into 3-4 doses (TID-QID) - **Route**: Oral - **Duration**: **10-14 days** or longer until symptoms resolve ### Dose Adjustments - **Renal Impairment**: Minimal systemic absorption from intact GI tract. For intestinal indications, generally **no dose adjustment** needed. Use with caution in severe impairment or if GI mucosal integrity is compromised (risk of increased absorption). - **Hepatic Impairment**: No specific dose adjustment guidelines; primarily renally eliminated if absorbed. - **Elderly Patients**: No specific dose adjustment; consider lower starting dose due to potential for decreased renal function and comorbidities. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Consult infectious disease specialist; data are limited. - **Frequency**: Consult specialist - **Maximum**: N/A - **Special Notes**: Use with extreme caution due to immature renal function and potential for increased systemic absorption in immature GI tracts, leading to nephrotoxicity/ototoxicity. ### Infants (1-12 months) - **Intestinal Amebiasis**: - **Dose**: **25-35 mg/kg/day** - **Frequency**: Divided into 3 doses (TID) - **Maximum**: **1.5 g/day** - **Cryptosporidiosis**: - **Dose**: **25-35 mg/kg/day** - **Frequency**: Divided into 3-4 doses (TID-QID) - **Maximum**: **1.5 g/day** - **Special Notes**: Monitor closely for GI upset (diarrhea, nausea) and signs of systemic toxicity if absorption occurs. ### Children (1-12 years) - **Intestinal Amebiasis**: - **Dose**: **25-35 mg/kg/day** - **Frequency**: Divided into 3 doses (TID) - **Maximum**: **1.5 g/day** - **Cryptosporidiosis**: - **Dose**: **25-35 mg/kg/day** (up to **50 mg/kg/day** in severe cases) - **Frequency**: Divided into 3-4 doses (TID-QID) - **Maximum**: **2.25 g/day** - **Special Notes**: Administer with meals to reduce GI side effects. Ensure adequate hydration. ### Adolescents (13-18 years) - **Dose**: Follow adult dosing recommendations **(25-35 mg/kg/day)** based on weight, or typical adult doses up to maximums. - **Maximum**: **1.5 g/day** for amebiasis; **2.25 g/day** for cryptosporidiosis. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to paromomycin or other aminoglycosides. - **Absolute**: Intestinal obstruction (risk of systemic absorption leading to toxicity). - **Relative**: Pre-existing hearing loss or severe renal impairment (increased risk of ototoxicity/nephrotoxicity if systemic absorption occurs). ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, abdominal cramps, nausea. - **Common (1-10%)**: Vomiting, heartburn, steatorrhea. - **Serious but Rare**: Ototoxicity (tinnitus, hearing loss, vertigo), nephrotoxicity (elevated creatinine), malabsorption syndrome (with prolonged high-dose use), superinfection (e.g., *C. difficile*). ### Key Drug Interactions - **Other Aminoglycosides (e.g., Gentamicin)**: Increased risk of ototoxicity and nephrotoxicity if significant systemic absorption occurs. Avoid concurrent use if possible. - **Nephrotoxic Drugs (e.g., Amphotericin B, NSAIDs, Vancomycin)**: Increased risk of renal toxicity if systemic absorption of paromomycin occurs. Monitor renal function. - **Ototoxic Drugs (e.g., Loop Diuretics)**: Increased risk of hearing loss and vestibular toxicity. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (BUN, creatinine) if concern for mucosal damage or prolonged use. Baseline audiometry not routinely needed for oral use. - **During Treatment**: Monitor for resolution of symptoms. Monitor for new or worsening diarrhea (consider *C. difficile*). - **Clinical Signs**: Watch for signs of systemic absorption/toxicity: decreased urine output, tinnitus, hearing changes, dizziness. ## Clinical Pearls - 💡 **Administer with meals**: Helps reduce gastrointestinal side effects like nausea and stomach upset. - 💡 **Poor systemic absorption**: Paromomycin works primarily in the gut lumen, making it ideal for intestinal infections with minimal systemic effects when the GI tract is intact. - 💡 **Complete the full course**: Even if symptoms improve, completing the full duration is crucial to eradicate the parasite and prevent relapse. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.